Therapeutic Goods
From 1 January 2026, the Therapeutic Goods Administration (TGA) moved to a stricter, more proactive compliance posture. The TGA 2026 compliance principles set out a risk-based enforcement approach across a defined set of priority areas, including medicinal cannabis, vaping products and weight loss medications. For prescribers, pharmacists and allied health practitioners, the shift means closer scrutiny and a higher expectation of documentation.
What the 2026 compliance principles change
The TGA has described its compliance principles as a move from reactive responses to proactive, risk-based enforcement. The principles outline how and why the regulator acts and are intended to guide enforcement through 2027, with a full review scheduled for late 2027. They followed a review of the TGA 2023-2025 compliance priorities and represent one of the more comprehensive shifts in the regulator enforcement approach in recent years.
Where the TGA is focusing
The compliance framework targets a set of priority areas, with medicinal cannabis, vaping products and weight loss medications among those drawing particular attention. For pharmacists, the TGA has signalled scrutiny of compounding practices and substitution decisions, including investigation of substandard compounded preparations and an expectation that pharmacies verify suppliers and maintain documentation. For prescribers of high-risk medications such as medicinal cannabis and weight loss drugs, prescribing must follow approved pathways and indications, and off-label use carries additional documentation requirements.
Advertising and permitted indications
The TGA focus extends to advertising. Allied health practitioners who advertise therapeutic goods must comply with permitted indications, and exaggerated claims about supplements or devices can attract enforcement action. The broader message is that the TGA expects claims, prescribing and supply to be evidence-based and properly documented.
What this means for the personal injury sector
For insurers and claims teams, the sharper TGA enforcement is a useful signal. Where claims involve medicinal cannabis, compounded preparations or weight loss medications, regulatory expectations around appropriate prescribing, documentation and supply are now more clearly defined. That makes independent clinical review of medication regimens more valuable, both to confirm that treatment is appropriate and to identify regimens that sit outside approved pathways.
Key Takeaways
- The TGA 2026 compliance principles took effect on 1 January 2026.
- Enforcement is shifting from reactive to proactive, risk-based action.
- Priority areas include medicinal cannabis, vaping products and weight loss medications.
- Pharmacists face scrutiny of compounding and substitution, and prescribers must follow approved pathways with proper documentation.
Frequently Asked Questions
What is the TGA 2026 compliance crackdown?
It is the stricter, risk-based enforcement approach of the TGA, set out in its 2026 compliance principles, which took effect on 1 January 2026.
Which areas is the TGA prioritising?
Priority areas include medicinal cannabis, vaping products and weight loss medications, alongside scrutiny of compounding and advertising.
How long do the compliance principles apply?
The principles guide enforcement through 2027, with a full review scheduled for late 2027.
Primary source: TGA compliance principles, 2026.
